Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262030 | 0.67 | — | — | |
| SCHEMBL506098 | 0.64 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9142256 | 0.63 | ATAD2 (0.32) | — | |
| SCHEMBL13863 | 0.63 | — | — | |
| SCHEMBL21566576 | 0.63 | — | — | |
| SCHEMBL10538971 | 0.63 | — | — | |
| SCHEMBL13779843 | 0.63 | — | — | |
| SCHEMBL9736365 | 0.62 | — | — | |
| SCHEMBL1094924 | 0.61 | — | — | |
| SCHEMBL18155166 | 0.60 | HDAC8 (0.33) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288042-A1 | STABLE HIGHLY PURE AZACITIDINE AND PREPARATION METHODS THEREFOR | CHEMAGIS LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| EP-2176279-A2 | STABLE HIGHLY PURE AZACITIDINE AND PREPARATION METHODS THEREFOR | Chemagis Ltd. (IL) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009016617-A2 | STABLE HIGHLY PURE AZACITIDINE AND PREPARATION METHODS THEREFOR | CHEMAGIS LTD. (IL) | 2009-02-05 | — | — | WO | disclosed |
| US-4058602-A | LEUKEMIA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288042-A1 | STABLE HIGHLY PURE AZACITIDINE AND PREPARATION METHODS THEREFOR | UNG, DCTD, CDA | PDPK1 2891/4885ALDH1A1 460/4885CYP1A2 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.